Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding

Summary

Carvedilol versus endoscopic band ligation for primary prophylaxis of oesophageal variceal bleeding in cirrhotic patients with arterial hypertension

Eligibility

Inclusion Criteria:

* • Aged \>18 years

  * Cirrhotic patients with arterial hypertension
  * Endoscopic evidence of medium/large-sized esophageal varices

Exclusion Criteria:

* • History of variceal bleeding or previous primary prevention of varices.

  * Portal vein thrombosis or previous porto-systemic shunts as TIPS.
  * Patients on drugs affecting portal pressure (beta blockers, nitrates).
  * Advanced cardiovascular disease including acute myocardial infarction, atrio-ventricular block, congestive heart failure, chronic peripheral ischemia, severe bradycardia.
  * Patients with severe respiratory diseases (COPD, bronchial asthma).
  * Uncontrolled diabetes mellitus
  * Renal impairment
  * Hepatocellular carcinoma
  * Allergy to carvedilol
  * Pregnancy or lactation

Conditions2

Interventions1

Related trials

• Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis. — Institute of Liver and Biliary Sciences, India
• Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis — Asian Institute Of Medical Sciences
• DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis — Post Graduate Institute of Medical Education and Research, Chandigarh
• Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC — Taipei Veterans General Hospital, Taiwan
• Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease — Chinese University of Hong Kong
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity — SWOG Cancer Research Network
• Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator — University of Rochester

Browse More Trials